加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.87
+US$0.01 · +0.54%
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
前收盘价
US$1.87
+US$0.01 · +0.54%
盘中时间采用ET。市场数据可能有所延迟。
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
日内区间
当前US$1.87
52周区间
当前US$1.87
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
38
偏贵
情绪
58
多空交织
风险
82
极高风险
动量
25
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
日内区间
当前US$1.87
52周区间
当前US$1.87
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
